B2M and hepatocellular carcinoma: Using the selective MEK inhibitor trametinib and PI3K inhibitor buparlisib, we revealed that inhibition of the MEK/ERK pathway, but not of the PI3K/AKT pathway, enhanced STAT1 activation and subsequent expression of cell surface HLA-I and B2M molecules in HCC cell lines.